• Solasia enters new license alliance with Maruho biospectrumasia
    December 12, 2019
    Japan based Solasia Pharma K.K. has announced that it has entered into an exclusive license agreement with Maruho Co., Ltd. for the commercialization of Solasia’s product SP-04 (PledOx®), a therapeutic agent for chemotherapy induced peripheral neuropathy
PharmaSources Customer Service